{"id":"bayesian-prediction-tacrolimus-dosage","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bayesian prediction models use population pharmacokinetic data and individual patient characteristics to forecast tacrolimus blood concentrations and optimize dosing. This computational approach aims to achieve therapeutic drug levels more rapidly and accurately than standard dosing, reducing the need for frequent therapeutic drug monitoring adjustments. The tool is applied to tacrolimus, a calcineurin inhibitor immunosuppressant.","oneSentence":"This is a Bayesian prediction tool for personalizing tacrolimus dosing based on individual patient pharmacokinetics, not a drug itself.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:40:06.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Optimization of tacrolimus dosing in transplant recipients and autoimmune disease patients"}]},"trialDetails":[{"nctId":"NCT06529536","phase":"PHASE4","title":"Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-08-05","conditions":"Solid Organ Transplant","enrollment":45},{"nctId":"NCT03465410","phase":"PHASE4","title":"OPTImization of the Dose of tacroliMUS by Bayesian Prediction","status":"COMPLETED","sponsor":"NURIA LLOBERAS BLANCH","startDate":"2017-03-21","conditions":"KIDNEY TRANSPLANTATION","enrollment":96},{"nctId":"NCT00975663","phase":"PHASE4","title":"Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation","status":"TERMINATED","sponsor":"University Hospital, Limoges","startDate":"2009-09","conditions":"Lung and Heart-lung Transplantation","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tacrolimus"],"phase":"marketed","status":"active","brandName":"Bayesian Prediction Tacrolimus dosage","genericName":"Bayesian Prediction Tacrolimus dosage","companyName":"NURIA LLOBERAS BLANCH","companyId":"nuria-lloberas-blanch","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a Bayesian prediction tool for personalizing tacrolimus dosing based on individual patient pharmacokinetics, not a drug itself. Used for Optimization of tacrolimus dosing in transplant recipients and autoimmune disease patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}